Deutsche Bank Reaffirms Their Sell Rating on Roche Holding AG (RHHVF)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Papadakis is a 4-star analyst with an average return of 3.5% and a 51.43% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Novartis AG, and AstraZeneca.
In addition to Deutsche Bank , Roche Holding AG also received a Sell from J.P. Morgan's Richard Vosser in a report issued yesterday. However, on July 17, Berenberg Bank maintained a Hold rating on Roche Holding AG (Other OTC: RHHVF).
The company has a one-year high of $354.19 and a one-year low of $269.80. Currently, Roche Holding AG has an average volume of 11.61K.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
4 hours ago
- Globe and Mail
Meenyon Unveils Comprehensive Forklift Portfolio, Featuring the Diesel Hercules Series and Next-Generation Electric Models
Meenyon, a global pioneer in industrial vehicles and intelligent handling solutions, today announced a major expansion of its forklift portfolio, unveiling a powerful diesel lineup alongside its acclaimed electric forklift series. This strategic update further cements Meenyon's reputation as a premier supplier of clean, intelligent, and high-performance equipment for warehouses, ports, factories, and logistics centers across the globe. Since its founding in 2003, Meenyon has pursued one mission: to lead the material-handling sector with products that seamlessly blend productivity, safety, and sustainability. The company's latest offerings include the new Diesel Forklift Truck CPC/Q(D)20-35T3, a rugged internal combustion powerhouse designed to tackle the heaviest loads with exceptional efficiency, alongside its continually evolving line of zero-emission electric vehicles. Introducing the Hercules: CPC/Q(D)20-35T3 Diesel Forklift Truck – Strength Redefined Built to exceed expectations, the CPC(D)30T3 and CPC(D)35T3 models in the Diesel Forklift Truck CPC/Q(D)20-35T3 series provide unmatched load handling and versatility. With rated loads of 3.0 and 3.5 tons and maximum loads reaching 4.0 tons, these forklifts deliver the power and durability required in industrial operations, without compromising on operator comfort or safety. Key Product Highlights: Wide-view mast with cargo drop buffer for enhanced visibility Small-diameter steering wheel with adjustable angle for ergonomic operation Fore-and-aft adjustable seats for personalized comfort Xinchai high-torque diesel engine meeting national emission standards Mechanical gear shift with electronic hydraulic shift for seamless control Heat-insulated hood with sound-absorbing materials to minimize noise and vibration Integrated safety features, including a solid-state instrument panel and overhead guard 'Meenyon's Hercules forklifts exceeded our expectations in load capacity. We look forward to a long-term collaboration,' noted a recent client from the automotive inspection industry who placed an immediate order after a successful on-site demo. Technical Excellence: Engine Models: 4D27G31 (30T3), 4D30G31 (35T3) Rated Power: 36.8 kW @ 2500 rpm Rated Torque: Up to 174 Nm Fuel Tank Capacity: 70 L Travel Speed: 20 km/h Lift Speed: 500/480 mm/s (no load/full load) Gradeability: 20% Turning Radius: 2620 mm Fork Dimensions: 1070 × 125 × 45/50 mm From enhanced mast options to field-tested traction and torque, the Hercules diesel series is built for reliability, performance, and cost-effectiveness in heavy-duty operations. Continued Innovation: Meenyon's Expanding Electric Forklift Line At the heart of Meenyon's zero-emission offering is the Electric Warehouse Reach Truck CQD16/20RV(F)2, purpose-built for high-racking operations up to 12 meters. This flagship model boasts: Ergonomic cockpit and unobstructed forward visibility High-load stability from an optimized mast design 500 Ah battery with 65 A fast charger for multi-shift capability Integrated side-shift system for rapid pallet positioning Supporting operations in narrow aisles and smaller environments, models like the EST122 Pedestrian Stacker, ESR151 Ride-On Stacker, ES16-RS, and ES12-16WA deliver adaptability, safety, and high throughput in compact formats. These units feature advanced safety profiles, spring-assist steering, onboard chargers, and AC-powered systems, all designed to meet the rigorous demands of today's fast-moving logistics centers. 'Electric forklifts are now the performance benchmark for modern logistics,' a Meenyon spokesperson stated. 'With our newest designs, customers no longer have to choose between power and sustainability, they can have both.' Engineering Excellence Meets Global Reach Meenyon's forklifts, whether diesel or electric, are manufactured to the highest standards, certified to SGS IATF 16949:2016 and compliant with CE, ANSI, and UL regulations. Every unit undergoes a multi-stage safety and performance test at Meenyon's in-house lab before being shipped, ensuring out-of-the-box reliability. With over 700,000 electric pallet trucks sold and a distribution network spanning more than 30 countries, Meenyon is a recognized name in both emerging and established markets. The company is also a key contributor to China's national industrial-vehicle standards and continues to push the envelope with ongoing R&D in automation, telematics, and hydrogen fuel-cell propulsion. Real Results, Real Partnerships A recent visit by an international client in the automotive inspection sector resulted in a confirmed order for two 4-ton diesel forklifts after witnessing the 3.5-ton Hercules model successfully handle 4-ton loads, proving itself a cost-effective alternative to heavier equipment. Shipment is expected within 40 days, and future resale partnerships are already under discussion. Explore the Meenyon Advantage Businesses seeking to upgrade their fleets with reliable, efficient, and environmentally conscious equipment are encouraged to explore Meenyon's comprehensive lineup. From diesel-powered heavy-lifters to whisper-quiet electric reach trucks, Meenyon offers the right solution for every industrial need. About Meenyon Founded in 2003, Meenyon is a leading designer and manufacturer of electric forklifts, pallet trucks, stackers, and intelligent handling robots. Headquartered in Shanghai and certified to SGS IATF 16949:2016, the company supplies OEM components to international automotive brands and partners with European and Asian forklift makers. With continuous investment in battery and hydrogen technologies, Meenyon is shaping the future of sustainable material handling. To learn more visit: For the latest updates, follow Meenyon on Social media. Media Contact Company Name: Meenyon (Jiaxing Meenyon Green Energy Technology Co., Ltd.) Contact Person: Xia Zaochun Email: Send Email City: Jiaxing City State: Zhejiang Province Country: China Website:
Globe and Mail
6 hours ago
- Globe and Mail
Advanced Ovarian Cancer Clinical Trial Pipeline Spotlight: 50+ Companies Racing to Develop Safe and Effective Therapies
DelveInsight's, 'Advanced Ovarian Cancer Pipeline Insight 2025' report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Ovarian Cancer pipeline landscape. It covers the Advanced Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Ovarian Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Advanced Ovarian Cancer Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Advanced Ovarian Cancer Pipeline Outlook Report Key Takeaways from the Advanced Ovarian Cancer Pipeline Report In July 2025, AstraZeneca announced a study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated. In July 2025, CanariaBio Inc. announced a study to compare the efficacy and safety of five administrations of oregovomab versus placebo, infused in schedule dependent sequence with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of patients with newly diagnosed advanced ovarian cancer who are planned to receive neoadjuvant treatment followed by interval debulking surgery (IDS) and adjuvant treatment. In July 2025, Incyte Corporation conducted a study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib. This study will only be open in the UK and EU. DelveInsight's Advanced Ovarian Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Ovarian Cancer treatment. The leading Advanced Ovarian Cancer Companies such as OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc. and others. Promising Advanced Ovarian Cancer Pipeline Therapies such as Topotecan, Paclitaxel, Carboplatin, Bevacizumab, Erlotinib, AZD0530, Olaparib and others. Discover how the Advanced Ovarian Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Advanced Ovarian Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Advanced Ovarian Cancer Clinical Trials and Studies Advanced Ovarian Cancer Emerging Drugs Profile Oregovomab: OncoQuest Oregovomab is a murine IgG against CA 125. Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in this phase II trial. In a randomized Phase II clinical trial of 97 patients, treatment with Oregovomab demonstrated a highly clinically significant outcome for both progression-free and overall survival favoring the addition of oregovomab to a standard of care chemotherapy combination of carboplatin and paclitaxel. The risk of progression and of death was reduced by more than 50% when compared to placebo, and safety data showed that oregovomab did not add incremental toxicity to the chemotherapy regimen. Stenoparib: Allarity Therapeutics Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. It is currently in Phase 2 testing for ovarian cancer with patients selected by the Stenoparib DRP. The Stenoparib DRP® is validated for ovarian cancer. It is currently being evaluated for the treatment of advanced ovarian cancer in a Phase 2 clinical trial at the Dana-Farber Cancer Institute using the Stenoparib DRP® companion diagnostic to guide patient enrollment and improve therapeutic outcome. DP-303c: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. DP-303c is under development for the treatment of HER2 low expressing solid tumors, gastric cancer including gastroesophageal junction, breast cancer, adenocarcinoma of the gastroesophageal junction, epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. The drug candidate is an antibody drug conjugate that is administered by intravenous route. It acts by targeting human epidermal growth factor receptor 2 (HER2). The Advanced Ovarian Cancer pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Ovarian Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Ovarian Cancer Treatment. Advanced Ovarian Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Advanced Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Ovarian Cancer market. Get a detailed analysis of the latest innovations in the Advanced Ovarian Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Advanced Ovarian Cancer Unmet Needs Advanced Ovarian Cancer Companies OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc. and others. Advanced ovarian cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical. Advanced Ovarian Cancer Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Advanced Ovarian Cancer Therapies and key Developments @ Advanced Ovarian Cancer Market Drivers and Barriers, and Future Perspectives Scope of the Advanced Ovarian Cancer Pipeline Report Coverage- Global Advanced Ovarian Cancer Companies- OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc. and others. Advanced Ovarian Cancer Pipeline Therapies- Topotecan, Paclitaxel, Carboplatin, Bevacizumab, Erlotinib, AZD0530, Olaparib and others. Advanced Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Advanced Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Advanced Ovarian Cancer drug development? Find out in DelveInsight's exclusive Advanced Ovarian Cancer Pipeline Report—access it now! @ Advanced Ovarian Cancer Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Advanced ovarian cancer: Overview Pipeline Therapeutics Therapeutic Assessment Advanced ovarian cancer – DelveInsight's Analytical Perspective In-depth Commercial Assessment Advanced ovarian cancer Collaboration Deals Late Stage Products (Phase III) Oregovomab: OncoQuest Drug profiles in the detailed report….. Mid Stage Products (Phase II) Stenoparib - Allarity Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) DS-6000a: Daiichi Sankyo Company Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Advanced ovarian cancer Key Companies Advanced ovarian cancer Key Products Advanced ovarian cancer- Unmet Needs Advanced ovarian cancer- Market Drivers and Barriers Advanced ovarian cancer- Future Perspectives and Conclusion Advanced ovarian cancer Analyst Views Advanced ovarian cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth Curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
6 hours ago
- Globe and Mail
Gerald Johnson elected to Eaton's Board of Directors
Intelligent power management company Eaton (NYSE:ETN) today announced that Gerald Johnson has been elected to the company's Board of Directors effective July 23, 2025. This press release features multimedia. View the full release here: Johnson is the retired executive vice president, Global Manufacturing and Sustainability, of General Motors, where he led the company's global manufacturing operations, labor relations and sustainable workplace practices. Over the course of his career, spanning more than 40 years at GM, he oversaw safety, quality and productivity, and held several roles of increasing responsibility, including vice president, Manufacturing and Labor Relations, North America, and vice president, Global Operational Excellence. He currently serves on the board of Caterpillar Inc. 'With his extensive experience in global manufacturing, engineering and operations, Gerald is a valuable addition to our Board,' said Paulo Ruiz, Eaton chief executive officer. 'As we continue our strategy to execute for growth at Eaton, I'm confident that Gerald's breadth of experience and proven performance in operations excellence, along with his strong customer focus, will serve our company well.' Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace and mobility markets. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we're helping to solve the world's most urgent power management challenges and building a more sustainable society for people today and generations to come. Founded in 1911, Eaton has continuously evolved to meet the changing and expanding needs of our stakeholders. With revenues of nearly $25 billion in 2024, the company serves customers in more than 160 countries. For more information, visit Follow us on LinkedIn.
